Alaunos Therapeutics, Inc. (TCRT)Healthcare | Biotechnology | Fort Lauderdale, United States | NasdaqCM
2.08 USD
+0.03
(1.659%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 2.10 +0.02 (0.763%) ⇧ (July 13, 2026, 6:46 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 5:49 a.m. EDT
The investment case here is structurally broken. The company is trading at a valuation of nearly 1,669 times sales with negative earnings and massive operating losses, signaling a business that is burning cash without generating revenue. This fundamental reality is compounded by a catastrophic multi-year price trajectory; the stock has lost 99.44% of its value over the last nine years, with six consecutive years of decline ending recently. While there was a brief spike in price recently, the broader trend remains deeply bearish, and the statistical models predicting a short-term bounce are unreliable given the lack of historical data integrity. With no dividend to provide income and a balance sheet showing significant cash outflows, this is a clear avoid for investors seeking capital preservation or growth. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.093821 |
| AutoARIMA | 0.097934 |
| MSTL_115 | 0.098840 |
| MSTL_60_115 | 0.111652 |
| AutoTheta | 0.132291 |
| AutoETS | 0.207212 |
| MSTL_60 | 0.281254 |
Forecast horizon: 60 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 23% |
| H-stat | 3.33 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.002 |
| Excess Kurtosis | 1.88 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.001 |
| Market Cap | 5,089,432 |
| Forward P/E | -3.47 |
| Beta | -1.02 |
| Previous Name | ZIOPHARM Oncology, Inc. |
| Website | https://www.alaunos.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.4875 |
| Address1 | 501 E. Las Olas Blvd. |
| Address2 | Suite 300 |
| All Time High | 2,400.0 |
| All Time Low | 1.31 |
| Ask | 2.4 |
| Ask Size | 1 |
| Audit Risk | 10 |
| Average Daily Volume10 Day | 23,340 |
| Average Daily Volume3 Month | 16,804 |
| Average Volume | 16,804 |
| Average Volume10Days | 23,340 |
| Beta | -1.023 |
| Bid | 1.74 |
| Bid Size | 1 |
| Board Risk | 9 |
| Book Value | 0.542 |
| City | Fort Lauderdale |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.084 |
| Current Ratio | 1.63 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 2.1 |
| Day Low | 2.03 |
| Display Name | Alaunos Therapeutics |
| Earnings Timestamp End | 1,755,201,600 |
| Earnings Timestamp Start | 1,755,201,600 |
| Ebitda | -4,130,500 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.136 |
| Enterprise To Revenue | 1,564.584 |
| Enterprise Value | 4,693,752 |
| Eps Forward | -0.6 |
| Eps Trailing Twelve Months | -2.16 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.3794 |
| Fifty Day Average Change | -0.2953999 |
| Fifty Day Average Change Percent | -0.124148905 |
| Fifty Two Week Change Percent | -48.75 |
| Fifty Two Week High | 6.2 |
| Fifty Two Week High Change | -4.1159997 |
| Fifty Two Week High Change Percent | -0.66387093 |
| Fifty Two Week Low | 1.67 |
| Fifty Two Week Low Change | 0.41400015 |
| Fifty Two Week Low Change Percent | 0.24790429 |
| Fifty Two Week Range | 1.67 - 6.2 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,124,890,200,000 |
| Float Shares | 1,896,443 |
| Forward Eps | -0.6 |
| Forward P E | -3.4733334 |
| Free Cashflow | -2,139,625 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 1 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -1,440,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.14507 |
| Held Percent Institutions | 0.06529 |
| Implied Shares Outstanding | 2,442,146 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.ziopharm.com/index.cfm |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,721,260,800 |
| Last Split Factor | 1:10 |
| Long Business Summary | Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida. |
| Long Name | Alaunos Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 5,089,432 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_11686323 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-11 |
| Net Income To Common | -4,215,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,006,399 |
| Open | 2.04 |
| Operating Cashflow | -3,128,000 |
| Operating Margins | -1,381.6667 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.58 |
| Phone | 346 355 4099 |
| Post Market Change | 0.015899897 |
| Post Market Change Percent | 0.76295084 |
| Post Market Price | 2.0999 |
| Post Market Time | 1,783,982,801 |
| Prev Name | ZIOPHARM Oncology, Inc. |
| Previous Close | 2.05 |
| Price Hint | 4 |
| Price To Book | 3.8450186 |
| Price To Sales Trailing12 Months | 1,696.4773 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.595 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.03400016 |
| Regular Market Change Percent | 1.6585443 |
| Regular Market Day High | 2.1 |
| Regular Market Day Low | 2.03 |
| Regular Market Day Range | 2.03 - 2.1 |
| Regular Market Open | 2.04 |
| Regular Market Previous Close | 2.05 |
| Regular Market Price | 2.084 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 7,282 |
| Return On Assets | -1.29434 |
| Return On Equity | -3.50298 |
| Revenue Per Share | 0.001 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 2,442,146 |
| Shares Percent Shares Out | 0.006 |
| Shares Short | 14,673 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 13,903 |
| Short Name | Alaunos Therapeutics, Inc. |
| Short Percent Of Float | 0.0064999997 |
| Short Ratio | 0.81 |
| Source Interval | 15 |
| State | FL |
| Symbol | TCRT |
| Total Cash | 354,000 |
| Total Cash Per Share | 0.146 |
| Total Debt | 0 |
| Total Revenue | 3,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.16 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.8893 |
| Two Hundred Day Average Change | -0.8053 |
| Two Hundred Day Average Change Percent | -0.27871802 |
| Type Disp | Equity |
| Volume | 7,282 |
| Website | https://www.alaunos.com |
| Zip | 33,301 |